AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JAN 9 - (NewsRx.com & NewsRx.net) -- Zometa (zoledronic acid for injection) significantly reduced the risk of developing a skeletal-related event (SRE) when compared to pamidronate disodium for injection (Aredia) in advanced breast cancer patients who were treated for up to 24 months, according to data presented at the San Antonio Breast Cancer Symposium.
These SREs include, among others, pathologic fractures, a need for radiation or surgery to bone, spinal cord compression and hypercalcemia. An intravenous bisphosphonate, Zometa is the first therapy of its kind to demonstrate efficacy in treating bone complications across a broad range of tumor types such as breast, prostate, lung and renal cell cancers. Further, Zometa offers patients, nurses and clinicians a convenient 4 mg, 15-minute infusion time.
"Bone metastases and their complications can be severely debilitating for advanced breast cancer patients. These new longer-term data suggest that Zometa offers these patients an effective and convenient treatment that reduces their risk of developing these complications," said Robert E. Coleman, MD, lead investigator and head of the Cancer Research Centre, University of Sheffield, England.
In this study, a multiple-event analysis demonstrated that breast cancer patients treated with Zometa 4 mg in a 15-minute infusion had a lower risk of developing skeletal complications (p=0.025) after 2 years of treatment, compared with those treated with pamidronate disodium for ...